Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587265 | 0.79 | BRD4 (0.54) | BRD4CREBBPPARP1CRBNHPGD | |
| SCHEMBL15691869 | 0.79 | BRD4 (0.54) | BRD4CREBBPPARP1CRBNHTR5A | |
| SCHEMBL3593434 | 0.76 | PARP1 (0.47) | PARP1CRBN | |
| SCHEMBL3596149 | 0.76 | PARP1 (0.49) | PARP1 | |
| SCHEMBL8149054 | 0.73 | BRD4 (0.47) | BRD4CREBBPPARP1CRBNMEN1 | |
| SCHEMBL3598102 | 0.72 | BRD4 (0.54) | BRD4CREBBPPARP1CRBNDDB1 | |
| SCHEMBL375101 | 0.71 | PARP1 (0.61) | BRD4CREBBPPARP1CRBN | |
| SCHEMBL3588408 | 0.71 | CRBN (0.42) | BRD4CREBBPCRBNDDB1MEN1 | |
| SCHEMBL677636 | 0.71 | BRD4 (1.00) | BRD4CREBBPCRBNBRD2 | |
| SCHEMBL1654363 | 0.71 | AHR (0.61) | PARP1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | BRD4 706/4885CREBBP 2015/4885PARP1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.